Intellia Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
The following table describes for the three months ended September 30, 2025 each trading arrangement under which our directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| John M. Leonard (President, CEO) | Adoption (September 11, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of (a) the close of trading on December 12, 2027; (b) the date that all shares of stock subject to the trading plan have been sold; and (c) the date on which the plan holder gives notice to terminate the plan. | 101,664 |
| Edward J. Dulac III (Executive VP, CFO) | Adoption (September 8, 2025) | Rule 10b5-1 trading arrangement | Sale | Until the earlier of (a) September 30, 2026; (b) the first date on which all trades have been executed or all trading orders related to such trades have expired; and (c) the date on which the plan holder gives notice to terminate the plan. | Indeterminable (1) |
(1) The number of shares that will be sold in accordance with this trading arrangement is indeterminable at the time of the filing of this Quarterly Report on Form 10-Q for the period ended September 30, 2025. Upon vesting of RSUs, it is our policy to immediately initiate a sell-to-cover in order to satisfy any applicable tax withholding obligations on behalf of the employee. The number of shares sold in the sell-to-cover will vary based on the market price of our common stock at the time of settlement. Any remaining shares held by Mr. Dulac after the sell-to-cover may be sold pursuant to the terms of this trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.